Fig. 2
From: Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Changes in tumor mutational burden during treatment. Parallel coordinate plots showing changes in tumor mutational burden (TMB) for individual breast cancers undergoing sequential epirubicin and docetaxel*. TMB was assessed by whole exome sequencing (WES) in pretreatment samples, post-epirubicin, and post-docetaxel. Y-axes indicate the TMB. Results are split by response groups: a objective response (CR, complete response, or PR, partial response) to both drugs. b Objective response to epirubicin; no response to docetaxel (SD, stable disease, or PD, progressive disease). c No response to epirubicin; objective response to docetaxel. d No response to either epirubicin or docetaxel. Green lines: CR, blue lines: PR, red lines: SD, purple lines: PD, gray line: non-evaluable response (NE). Single point, without line: only one biopsy available for analysis. Asterisk: hormone receptor positive, HER2 normal (HR+HER2−) tumors; triangle: HER2+ tumors; squares: triple-negative breast cancers (TNBC). A significant drop in TMB was observed under epirubicin treatment, among objective responders (p = 0.043; left sides of panels a and b). A significant drop in TMB was also observed under docetaxel treatment and non-responders (p = 0.006; right sides of panels b and d). *HER2-positive breast cancers received concomitant docetaxel and trastuzumab